Press Release: “Compass Pathways today announced statistically significant positive results in two pivotal Phase 3 trials evaluating COMP360” | Cannabis Law Report
Press Release Compass Pathways today announced statistically significant positive results in two pivotal Phase 3 trials evaluating COMP360 – a synthetic, proprietary formulation of psilocybin – in treatment-resistant depression (TRD). Notably, COMP360…
Read more Press Release: “Compass Pathways today announced statistically significant positive results in two pivotal Phase 3 trials evaluating COMP360” | Cannabis Law Report